Cantargia’s share issue of 20 MSEK fully subscribed
Lund, July 9, 2014 The completed share issue in Cantargia AB, directed to the shareholders in Lund University Bioscience AB, were fully subscribed. The share issue raises approximately 20 MSEK for Cantargia. Cantargia develops a unique pharmaceutical for leukemia, in which the cancer stem cells are killed and thereby eradicating the leukemia. The capital raised will enable Cantargia to start the final development steps for the drug, including toxicology, before initiating clinical trials. Cantargia’s project has created international interest and the company is currently discussing
